What are the limitations of the vhl syndrome surveillance checklist?

While the vhl syndrome surveillance checklist is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the vhl syndrome surveillance checklist to ensure safe bedside use and optimal diagnostic accuracy.

How does the vhl syndrome surveillance checklist compare to other Endocrinology scores?

The vhl syndrome surveillance checklist is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the vhl syndrome surveillance checklist free to use?

Yes. OpiCalc provides the vhl syndrome surveillance checklist completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

Vhl syndrome surveillance checklist Diagnostic Pathway

CLINICAL REFERENCE

CLINICAL INSIGHT

When to Use

Who Needs This?

Patients with a molecularly confirmed Von Hippel-Lindau (VHL) syndrome.
First-degree relatives of known VHL patients awaiting genetic testing results.
Evaluating clusters of VHL-associated tumors (e.g., bilateral RCC + cerebellar hemangioblastoma).

CLINICAL INSIGHT

How it Works

Annual High-Priority Screens

Retinal Exam: Annual ophthalmoscopy starting at age 5.
Blood Pressure: Regular monitoring for catecholamine crisis.
Biochemistry: Annual plasma/urine metanephrines starting at age 5 for early detection of Phaeochromocytoma.

Imaging Intervals

CNS (MRI Brain/Spine): Every 2 years starting at age 11–14.
Abdomen (MRI or Ultrasound): Annual or biennial starting at age 15 to screen for RCC and Pancreatic NETs.

CLINICAL INSIGHT

Practical Pearls

The "3.0 cm" Rule in RCC

In VHL-associated Renal Cell Carcinoma, surgical intervention (typically nephron-sparing surgery) is often delayed until the largest tumor reaches 3.0 cm. This balance minimizes the need for repeat surgeries and eventual dialysis while maintaining a low risk of metastasis.

Audiology Note

Endolymphatic sac tumors (ELST) are common in VHL and can cause sudden hearing loss. Patients should receive an audiology exam if hearing changes occur.

CLINICAL INSIGHT

Evidence Base

Primary Source

The VHL Handbook.

VHL Alliance.VHL Alliance Guidelines2020

When to Use

Who Needs This?

How it Works

Annual High-Priority Screens

Imaging Intervals

Practical Pearls

The "3.0 cm" Rule in RCC

Audiology Note

Evidence Base

Primary Source

VHL Syndrome Surveillance Checklist

When to Use

Who Needs This?

How it Works

Annual High-Priority Screens

Imaging Intervals

Practical Pearls

The "3.0 cm" Rule in RCC

Audiology Note

Evidence Base

Primary Source

VHL Syndrome Surveillance Checklist

Clinical Evidence and Methodology

When to Use

Who Needs This?

How it Works

Annual High-Priority Screens

Imaging Intervals

Practical Pearls

The "3.0 cm" Rule in RCC

Audiology Note

Evidence Base

Primary Source

VHL Syndrome Surveillance Checklist

Clinical Evidence and Methodology

When to Use

Who Needs This?

How it Works

Annual High-Priority Screens

Imaging Intervals

Practical Pearls

The "3.0 cm" Rule in RCC

Audiology Note

Evidence Base

Primary Source

VHL Syndrome Surveillance Checklist